WHO ICTRP trial
The influence of lispro Mix 50/50 and aspart Mix 30/70 on MAGE to diabetes
ChiCTR-IPR-15007340 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-IPR-15007340 |
|---|---|
| Public title | The influence of lispro Mix 50/50 and aspart Mix 30/70 on MAGE to diabetes |
| Scientific title | The influence of lispro Mix 50/50 and aspart Mix 30/70 on MAGE to diabetes |
| Primary sponsor | Nanjing First Hospital, Nanjing Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | diabetes |
| Interventions | A:lispro Mix 50/50-aspart Mix 30/70 ;B:aspart Mix 30/70-lispro Mix 50/50 |
| Registration date | Nov 4, 2015 |
| Target size | A:51;B:51 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: